Approval

AK111 Wins Second Approval

China approved Akeso's IL-17A antibody AK111 for active ankylosing spondylitis, its second indication after plaque psoriasis. The randomized, double-blind phase 3 AK111-303 trial reportedly met its primary ASAS20 and key secondary ASAS40 endpoints; numerical results were not provided. Akeso has a broader autoimmune portfolio, but AK111 faces substantial competition, making market access and commercial execution important to its uptake.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call